An Expanded Access Program for Elotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
ID Number 15-1781Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this expanded access program is to treat patients diagnosed with relapsed or refractory multiple myeloma with an investigational drug called elotuzumab.
An expanded access program is a means by which the Food and Drug Administration (FDA) enables manufacturers to make investigational drugs available, under certain circumstances, to treat a patient with a serious disease or condition who may benefit from treatment with the investigation drug, but who cannot participate in a controlled clinical trial of the investigational drug because of other health problems, age, or other factors, or are otherwise unable to enroll in such trials by any regulatory authorities.
Recruiting Patients: No